Premium
A Single Administration of Recombinant Human Interleukin‐12 Is Associated With Increased Expression Levels of Interferon‐gamma and Signal Transducer and Activator of Transcription in Healthy Subjects
Author(s) -
Trudeau Caroline,
Cotreau Monette M.,
Stonis Lucille,
Dykstra Kevin H.,
Oestreicher Judy L.,
Strahs Andrew,
Dorner Andrew J.,
Cleave Victor H. Van,
Trepicchio William L.,
Schwertschlag Ullrich S.
Publication year - 2005
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270005276116
Subject(s) - medicine , tolerability , pharmacokinetics , pharmacology , activator (genetics) , stat protein , recombinant dna , pharmacodynamics , cytokine , placebo , interferon , endocrinology , adverse effect , immunology , biology , signal transduction , receptor , stat3 , pathology , gene , biochemistry , alternative medicine
The objectives of this study were to assess the safety and tolerability of single doses of 1, 4, and 8 μg of recombinant human interleukin‐12 (rhIL‐12) administered subcutaneously to healthy subjects. The pharmacokinetics, pharmacodynamics, and pharmacogenomics of rhIL‐12 were evaluated. Recombinant human IL‐12 was well tolerated in these healthy male and female subjects. The most frequently reported adverse events were flu‐like symptoms, which exhibited a dose‐response relationship. Pharmacokinetic analysis suggested that serum IL‐12 levels increased with dose. Analysis of serum levels indicated that interferon‐γ increased with the dose of rhIL‐12, whereas IL‐6 levels showed no changes with rhIL‐12 treatment. The messenger ribonucleic acid expression of signal transducer and activator of transcription was significantly increased 24 hours after the administration of rhIL‐12 for all dose groups versus placebo, and results indicated that the magnitude of increase may be dose dependent. This study suggests that interferon‐γ and signal transducer and activator of transcription are biomarkers of rhIL‐12 activity.